ArticleRenal failure2022
Anti-PLA2R antibody measured by ELISA predicts the risk of vein thrombosis in patients with primary membranous nephropathy.
Article in Renal failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy.Frontiers in pharmacology · 2022Pooled it
- Renal Vein Thrombosis: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Non-diabetic kidney disease in a patient with type 2 diabetes mellitus: a case report.BMC nephrology · 2026Article
- Hypercoagulability and dyslipidemia in membranous nephropathy with anti-phospholipase A2 receptor antibodies.Renal failure · 2025Article
- A study on the association between serum antiphospholipase A2 receptor antibodies and the hypercoagulable state in Chinese patients with primary membranous nephropathy.Renal failure · 2025Article
- Prophylactic anticoagulation in patients with nephrotic syndrome in the Cure Glomerulonephropathy (CureGN) cohort.Clinical kidney journal · 2025Article
- Nomogram for thromboembolic events in primary membranous nephropathy associated with PLA2R antibody.Scientific reports · 2025Article
- Development of a venous thromboembolism risk prediction model for patients with primary membranous nephropathy based on machine learning.Frontiers in pharmacology · 2025Article
- The correlation between anti-phospholipase A2 receptor antibodies and hypercoagulability in patients with idiopathic membranous nephropathy.Renal failure · 2024Article
- The risk of thromboembolic events in patients with nephrotic syndrome and relatively high albumin levels: a study over 10 years.BMC nephrology · 2024Article
- Article
- Risk factors of venous thromboembolism in anti-PLA2R-positive and negative primary membranous nephropathy.Clinical kidney journal · 2022Article
- Serum Phospholipase A2 Receptor Antibody Is Associated with Thrombogenesis in Primary Membranous Nephropathy: A Systematic Review and Meta-Analysis.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary membranous nephropathy (PMN) is associated with the highest risk for developing venous thrombosis compared with other nephrotic diseases. The aim of the study was to assess the predictive value of the pathognomonic anti-phospholipase A2 receptor (PLA2R) antibody with regard to incidence of venous thrombosis in PMN.
methodsA total of 365 in-hospital patients diagnosed with PMN were enrolled in the study. Anti-PLA2R antibody was detected by commercial enzyme-linked immunosorbent assay. Multivariate logistic regression was used to detect the independent risk factors for venous thrombosis.
resultsThirty-seven patients (10.14%) had venous thrombosis. Patients with venous thrombosis had higher levels of cholesterol (CHOL), low-density lipoprotein (LDL), and D-dimer than those without venous thrombosis (
conclusionsAnti-PLA2R antibody was the independent risk factor for venous thrombosis in PMN. Larger prospective studies were warranted to verify the results in future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.